Metaxalone

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-21-D-0129

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Hauppauge, New York, UNITED STATES

SourceSAM
Documents2
This procurement notice announces the award of a national contract for the supply of Metaxalone tablets, managed by DLA Troop Support. The primary objective of this contract is to ensure a reliable and consistent supply of Metaxalone, a pharmaceutical product, to meet the needs of federal entities supported by DLA Troop Support. The scope of the contract encompasses the manufacturing and delivery of Metaxalone tablets, with all activities centered around pharmaceutical preparation as classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing). The place of performance for this contract is Hauppauge, New York, indicating that manufacturing, distribution, or logistical operations related to the contract will be based in this location. The contract falls under Product Service Code 6505, which pertains to drugs and biologicals, further emphasizing the pharmaceutical nature of the requirement. DLA Troop Support, a federal office, serves as the contracting entity responsible for overseeing contract execution and ensuring compliance with federal procurement standards. The contract is intended to support the agency’s mission of providing critical medical supplies to military and other federal customers, thereby contributing to the overall readiness and health of supported personnel. Key requirements for this contract include the ability to manufacture Metaxalone tablets in accordance with applicable regulatory standards and to deliver these products as specified by DLA Troop Support. Contractors are expected to maintain high standards of quality, reliability, and compliance throughout the contract lifecycle. The intended outcome is to secure a dependable source of Metaxalone tablets, minimizing supply disruptions and ensuring timely fulfillment of federal demand. The notice is currently active and was posted on May 23, 2022. Interested parties seeking further information or clarification may contact the primary point of contact, Ryan Ferry, at [email protected] or 215-737-3182, or the secondary contact, Denise Taubman, at [email protected] or 215-737-6877. This award notice is relevant for contractors with capabilities in pharmaceutical preparation manufacturing, particularly those with experience in producing and supplying prescription medications to federal agencies. The contract does not specify set-aside requirements or special considerations in the provided information. Contractors should review the full notice and any attached documents via the official SAM.gov opportunity page for additional details and compliance requirements.